[Recommendations for management of severe sepsis and septic shock. Surviving sepsis campaign].
Martin
C
C
Département d'anesthésie-réanimation et centre de traumatologie, hôpital Nord, boulevard Pierre-Dramard, 13915 Marseille cedex 20, France. martin@mail.ap-hm.fr
Garnier
F
F
Vallet
B
B
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000890:Anti-Infective Agents / Q000627:therapeutic use; D001639:Bicarbonates; D001786:Blood Glucose; D001810:Blood Volume; D002316:Cardiotonic Agents / Q000627:therapeutic use; D005343:Fibrinolytic Agents; D006801:Humans; D011486:Protein C / Q000627:therapeutic use; D011994:Recombinant Proteins / Q000627:therapeutic use; D012121:Respiration, Artificial; D012151:Resuscitation; D018805:Sepsis / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy / Q000628:therapy*; D012772:Shock, Septic / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy / Q000628:therapy*; D014662:Vasoconstrictor Agents / Q000627:therapeutic use
D000305:Adrenal Cortex Hormones; D000890:Anti-Infective Agents; D001639:Bicarbonates; D001786:Blood Glucose; D002316:Cardiotonic Agents; D005343:Fibrinolytic Agents; D011486:Protein C; D011994:Recombinant Proteins; D014662:Vasoconstrictor Agents; C421124:drotrecogin alfa activated